<DOC>
	<DOCNO>NCT01375179</DOCNO>
	<brief_summary>This study design proof concept KRP203 induction remission ulcerative colitis ( UC ) . The purpose study evaluate clinical benefit KRP203 subject moderately active refractory ulcerative colitis . The study provide safety tolerability data subject population eight week treatment KRP203 . Additionally , study evaluate duration clinical response KRP203 follow respond subject additional 12 week .</brief_summary>
	<brief_title>Efficacy &amp; Safety Moderately Active Refractory Ulcerative Colitis Patients</brief_title>
	<detailed_description>This multi-centre , double-blind , placebo control , parallel group , proof concept study evaluate efficacy , safety tolerability KRP203 subject moderately active refractory ulcerative colitis subject . In total , approximately 72 subject randomize study . After 30 patient complete 8 week treatment period KRP203 placebo , interim analysis determine preliminary efficacy . The study consist 28 day screen period ( day -35 -8 ) , baseline period ( day -7 day -1 ) , treatment period ( day 1 day 56 ) , follow-up period study completion .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Active disease define partial Mayo score modify Baron score disease extend least 25 cm anal verge Subjects must inadequately respond intolerance 5ASA therapy Subjects receive treatment UC ( 5ASAs steroid ) within time frame mention protocol Past recent history significant medical illness and/or clinically significant lab abnormality include limited hematology , clinical chemistry , urine analysis , ECG abnormality , HIV , Hepatitis B/C Presence history underlie metabolic , endocrine , hematologic , pulmonary , ophthalmic , cardiac , blood , renal , hepatic , infectious , psychiatric medically unstable condition , assess primary treating physician , opinion investigator , would immunocompromise subject and/or place subject unacceptable risk participation study immunomodulatory therapy Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Inflammatory Bowel disease</keyword>
	<keyword>Ulcerative colitis</keyword>
</DOC>